BRAF and melanoma: Three international clinical trials explored this approach in unresectable/metastatic BRAF-mutant melanoma patients: the phase III IMspire 150 (atezolizumab + vemurafenib/cobimetinib vs. vemurabenib/cobimetinib) [156], the phase I/II KEYNOTE-022 (pembrolizumab + dabrafenib/trametinib vs. dabrafenib/trametinib) [157], and the phase III COMBI-i (spartalizumab + dabrafenib/trametinib vs. dabrafenib/trametinib) [158].